Please assess the completion status of the following clinical trial:

Trial Title: Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Consent to biopsy at start and end of therapy~* Suspicion of Lichen sclerosus~* Pre-menopausal~* Age ≥18 years~Exclusion Criteria~* Prior surgery at the vulva, with exception of episiotomy~* Pregnancy~* Signs of infection with human papilloma virus at the vulva~* Vulvar intraepithelial neoplasia (VIN)~* Known generalised autoimmune disease~* Lichen sclerosus since childhood~* Prior therapy with topic clobetasol propionate or other immunosuppressives (tacrolimus or pimecrolimus) at the vulva~* Atopic diathesis and/or contact allergy~* Systemic immunosuppressive therapy~* Genital infection within the last four weeks (eg., condyloma acuminata, candidiasis)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
- 2 (Type: EXPERIMENTAL): Progesterone 8%, topical application, once daily about 2 g, during 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).